Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Brigham and Women's Hospital · Harvard University · +5 more institutions
Abstract
Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technology. Using prostate cancer as a model, we report docetaxel (Dtxl)-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A10 2'-fluoropyrimidine RNA aptamers that recognize the extracellular domain of the prostate-specific membrane antigen (PSMA), a well characterized antigen expressed on the surface of prostate cancer cells. These Dtxl-encapsulated nanoparticle-aptamer bioconjugates (Dtxl-NP-Apt) bind to the PSMA protein expressed on the…
Citation impact
- FWCI
- 35.30
- Percentile
- 100%
- References
- 44
Authors
8- OCOmid C. FarokhzadCorresponding
Brigham and Women's Hospital, Harvard University, Massachusetts Institute of Technology
- JCJianjun Cheng
University of Illinois Urbana-Champaign, Massachusetts Institute of Technology
- BABenjamin A. Teply
Massachusetts Institute of Technology
- ISInes Sherifi
Massachusetts Institute of Technology
- SJSangyong Jon
Gwangju Institute of Science and Technology
Topics & keywords
- LNCaP
- Aptamer
- In vivo
- Prostate cancer
- Chemistry
- Glutamate carboxypeptidase II
- Cancer research
- In vitro